Effect of interferon-alpha 2b on cryoglobulinemia related to hepatitis C virus infection. 1992

J M Durand, and G Kaplanski, and P Lefevre, and M A Richard, and L Andrac, and C Trepo, and J Soubeyrand

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D003449 Cryoglobulinemia A condition characterized by the presence of abnormal quantities of CRYOGLOBULINS in the blood. Upon cold exposure, these abnormal proteins precipitate into the microvasculature leading to restricted blood flow in the exposed areas. Cryoglobulinemias
D005260 Female Females
D006526 Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown. Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted,Parenterally-Transmitted Non-A, Non-B Hepatitis,PT-NANBH,Parenterally Transmitted Non A, Non B Hepatitis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077190 Interferon alpha-2 Alpha interferon encoded by the human IFNA2 gene. Recombinant forms are used in the treatment of CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; KAPOSI SARCOMA; MELANOMA; and HAIRY CELL LEUKEMIA. IFN-alpha 2,IFN-alpha-2,IFNalpha-2b, Recombinant,Interferon alfa-2a,Interferon alfa-2b,Interferon alpha-2b, Recombinant,Interferon alpha-A,Interferon-alpha 2,Intron A (Interferon),LeIF A,Reaferon,Recombinant Interferon alpha-2a,Recombinant Interferon alpha-2b,Ro 22-8181,Roferon-A,Sch-30500,Viferon,IFNalpha 2b, Recombinant,Interferon alfa 2a,Interferon alfa 2b,Interferon alpha 2,Interferon alpha 2b, Recombinant,Interferon alpha A,Interferon alpha-2a, Recombinant,Recombinant IFNalpha-2b,Recombinant Interferon alpha 2a,Recombinant Interferon alpha 2b,Ro 22 8181,Ro 228181,Roferon A,RoferonA,Sch 30500,Sch30500
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D016898 Interferon-alpha One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells. In addition to antiviral activity, it activates NATURAL KILLER CELLS and B-LYMPHOCYTES, and down-regulates VASCULAR ENDOTHELIAL GROWTH FACTOR expression through PI-3 KINASE and MAPK KINASES signaling pathways. Interferon Alfa,Interferon, Leukocyte,Interferon, Lymphoblast,alpha-Interferon,IFN-alpha D,IFN-alpha5,Interferon alpha-1,Interferon alpha-17,Interferon alpha-4,Interferon alpha-5,Interferon alpha-7,Interferon alpha-88,Interferon alpha-J,Interferon alpha-T,Interferon alpha4,Interferon alpha5,Interferon, Lymphoblastoid,Interferon, alpha,LeIF I,LeIF J,Leif D,IFN alpha D,IFN alpha5,Interferon alpha,Interferon alpha 1,Interferon alpha 17,Interferon alpha 4,Interferon alpha 5,Interferon alpha 7,Interferon alpha 88,Interferon alpha J,Interferon alpha T,Leukocyte Interferon,Lymphoblast Interferon,Lymphoblastoid Interferon,alpha Interferon

Related Publications

J M Durand, and G Kaplanski, and P Lefevre, and M A Richard, and L Andrac, and C Trepo, and J Soubeyrand
January 1993, Infection,
J M Durand, and G Kaplanski, and P Lefevre, and M A Richard, and L Andrac, and C Trepo, and J Soubeyrand
December 1992, Clinical rheumatology,
J M Durand, and G Kaplanski, and P Lefevre, and M A Richard, and L Andrac, and C Trepo, and J Soubeyrand
October 1994, The American journal of medicine,
J M Durand, and G Kaplanski, and P Lefevre, and M A Richard, and L Andrac, and C Trepo, and J Soubeyrand
April 2007, Digestive diseases and sciences,
J M Durand, and G Kaplanski, and P Lefevre, and M A Richard, and L Andrac, and C Trepo, and J Soubeyrand
March 1993, The American journal of gastroenterology,
J M Durand, and G Kaplanski, and P Lefevre, and M A Richard, and L Andrac, and C Trepo, and J Soubeyrand
September 1996, Transfusion science,
J M Durand, and G Kaplanski, and P Lefevre, and M A Richard, and L Andrac, and C Trepo, and J Soubeyrand
February 1998, Journal of hepatology,
J M Durand, and G Kaplanski, and P Lefevre, and M A Richard, and L Andrac, and C Trepo, and J Soubeyrand
July 1997, Journal of hepatology,
J M Durand, and G Kaplanski, and P Lefevre, and M A Richard, and L Andrac, and C Trepo, and J Soubeyrand
January 2002, Clinical and experimental rheumatology,
J M Durand, and G Kaplanski, and P Lefevre, and M A Richard, and L Andrac, and C Trepo, and J Soubeyrand
December 1997, Journal of clinical gastroenterology,
Copied contents to your clipboard!